Trial
NCT03983252
Effect of Alemtuzumab on Microglial Activation Positron Emission Tomography (PET) in Multiple Sclerosis
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Brigham and Women's Hospital
Collaborators
Genzyme, a Sanofi Company
Condition
Multiple Sclerosis
Intervention
[F-18]PBR06
Why stopped
The study was terminated without recruitment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-10-20